Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Haning

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Progress in Medicinal Chemistry|May 31, 2003
Phosphodiesterase type 5 (PDE5) inhibitorsHelmut Haning, Ulrich Niewöhner, Erwin Bischoff
Bioorganic & Medicinal Chemistry Letters|July 5, 2005
Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitorsHelmut Haning, Ulrich Niewöhner, Thomas Schenke, et al.
Bioorganic & Medicinal Chemistry Letters|May 15, 2007
Novel heterocyclic thyromimetics. Part 2Helmut Haning, Ulrich Mueller, Gunter Schmidt, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2002
Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitorsHelmut Haning, Ulrich Niewöhner, Thomas Schenke, et al.
Drug Discovery Today|December 19, 2018
An approach towards enhancement of a screening library: The Next Generation Library Initiative (NGLI) at Bayer - against all odds?Markus Follmann, Hans Briem, Andreas Steinmeyer, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2005
Novel heterocyclic thyromimeticsHelmut Haning, Michael Woltering, Ulrich Mueller, et al.
Organic & Biomolecular Chemistry|March 3, 2011
Total synthesis of the Amaryllidaceae alkaloid clivonineHelmut Haning, Carles Giró-Mañas, Victoria L Paddock, et al.
Chemmedchem|June 18, 2015
Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary DiseasesFranz von Nussbaum, Volkhart M-J Li, Swen Allerheiligen, et al.
Chemmedchem|June 5, 2023
European Medicinal Chemistry Leaders in Industry (EMCL) - On the Status and Future of Medicinal Chemistry Research in EuropeAmjad Ali, Marcus Bauser, Sophie Bertrand, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Progress in Medicinal Chemistry|May 31, 2003
Phosphodiesterase type 5 (PDE5) inhibitorsHelmut Haning, Ulrich Niewöhner, Erwin Bischoff
Bioorganic & Medicinal Chemistry Letters|July 5, 2005
Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitorsHelmut Haning, Ulrich Niewöhner, Thomas Schenke, et al.
Bioorganic & Medicinal Chemistry Letters|May 15, 2007
Novel heterocyclic thyromimetics. Part 2Helmut Haning, Ulrich Mueller, Gunter Schmidt, et al.
Bioorganic & Medicinal Chemistry Letters|April 18, 2002
Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitorsHelmut Haning, Ulrich Niewöhner, Thomas Schenke, et al.
Drug Discovery Today|December 19, 2018
An approach towards enhancement of a screening library: The Next Generation Library Initiative (NGLI) at Bayer - against all odds?Markus Follmann, Hans Briem, Andreas Steinmeyer, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2005
Novel heterocyclic thyromimeticsHelmut Haning, Michael Woltering, Ulrich Mueller, et al.
Organic & Biomolecular Chemistry|March 3, 2011
Total synthesis of the Amaryllidaceae alkaloid clivonineHelmut Haning, Carles Giró-Mañas, Victoria L Paddock, et al.
Chemmedchem|June 18, 2015
Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary DiseasesFranz von Nussbaum, Volkhart M-J Li, Swen Allerheiligen, et al.
Chemmedchem|June 5, 2023
European Medicinal Chemistry Leaders in Industry (EMCL) - On the Status and Future of Medicinal Chemistry Research in EuropeAmjad Ali, Marcus Bauser, Sophie Bertrand, et al.
Pageof 1